1月16日上午，位于连云港市海州工业园的江苏谦仁生物科技有限公司(以下简称"谦仁生物")首款产品"盐酸乙哌立松片(商品名：谦速)"正式举行上市发车 仪式，一批承载着科技创新力量的药品从这里启程，奔赴临床一线。这不仅标志着谦仁生物实现了从研发到产业化的关键跨越，更奏响了海州区生物医药 产业从"创新蓄能"向"成果释放"转型的激昂乐章，彰显了"海州智造"在高端医药领域的硬核实力。 生物医药产业作为战略性新兴产业，是衡量区域科技创新实力与产业竞争力的重要标志。此次谦速的成功上市，既是谦仁生物创新发展的里程碑，也是海 州区生物医药产业集聚发展的新起点。未来，海州区将持续优化产业生态，汇聚创新资源，推动生物医药产业向价值链高端攀升；谦仁生物也将继续加大 研发与生产投入，以更多优质药物惠及广大患者，助力海州打造区域性生物医药创新转化高地，为健康中国建设与地方经济高质量发展贡献更大力量。 一款药品从实验室到货架，往往要经历"十年磨一剑"的坚守与攻关。作为中枢性肌肉松弛剂领域的优质新品，谦速于2025年12月16日顺利获得国家药品监 督管理局批准上市，专为缓解肩周炎、腰痛症、颈椎病等引发的肌紧张状态及相关痉挛性麻痹症状而生。依 ...

Core Viewpoint - The recent annual report of Kew Flower Pharmaceutical (葵花药业) for 2024 indicates a revenue of 3.377 billion yuan and a net profit of 492 million yuan, reflecting the company's resilience amid industry challenges such as medical insurance cost control and large-scale drug procurement [1][2]. Financial Performance - In Q1 2024, Kew Flower achieved total revenue of 663 million yuan and a net profit attributable to shareholders of 57.11 million yuan [1]. - The company's contract liabilities increased significantly from less than 100 million yuan in Q3 to 284 million yuan in Q4, indicating potential future revenue and profit growth [2]. - Despite a year-on-year decline in Q1 2025 revenue, there was a notable 62% quarter-on-quarter growth, suggesting a positive trend in business recovery [2]. Dividend Policy - Kew Flower plans to distribute a cash dividend of 5 yuan per 10 shares, totaling approximately 292 million yuan, which represents 59.34% of the net profit attributable to shareholders [3]. - The company has a history of high dividend payouts, having distributed a total of 4.045 billion yuan since its listing, reflecting strong profit quality and management confidence in sustainable growth [3]. Brand Strategy - Kew Flower operates under two main brands: "Kew Flower" for adult medications and "Little Kew Flower" for children's medications, with the latter covering over 60 types of pediatric drugs and maintaining a leading market position [4][5]. - The "Little Kew Flower" brand has achieved a market share of 73% in its category, showcasing its competitive strength [4]. Marketing and Distribution - The company is enhancing its marketing channels and operational efficiency through digital transformation, including the establishment of self-operated B2B and B2C platforms [6]. - Kew Flower's sales expenses decreased by 68.46% to 431 million yuan in 2024, demonstrating significant cost reduction efforts [6]. - Collaborations with local pharmacies have resulted in substantial sales growth, with O2O channels experiencing increases of 35.4% and 38.8% [7]. Future Outlook - Kew Flower's strategic focus on brand empowerment and flow-driven models is expected to provide sustainable growth momentum, even in a challenging industry environment [7]. - The company aims to leverage its strong product portfolio to stabilize performance and deliver long-term returns to investors [7].